Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE)